Valencia, Spain

Joaquín Panadero Romero


Average Co-Inventor Count = 21.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Joaquín Panadero Romero: Innovator in Cardiotoxicity Prediction

Introduction

Joaquín Panadero Romero is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.

Latest Patents

Joaquín Panadero Romero holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as a biomarker for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout his career, Joaquín has worked with esteemed institutions such as the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. His work has focused on advancing medical research and improving treatment methodologies for cancer patients.

Collaborations

Joaquín has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and refinement of his innovative research.

Conclusion

Joaquín Panadero Romero is a pioneering inventor whose work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. His contributions have the potential to enhance patient safety and improve therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…